We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Carolina Liquid Chemistries and Diazyme Enter Into Partnership

By LabMedica International staff writers
Posted on 24 Jan 2023
Print article
Image: DZ-Lite c270 Benchtop Chemistry Analyzer (Photo courtesy of Carolina Liquid Chemistries)
Image: DZ-Lite c270 Benchtop Chemistry Analyzer (Photo courtesy of Carolina Liquid Chemistries)

Carolina Liquid Chemistries, Corp. (CLC, Greensboro, NC, USA) and Diazyme Laboratories, Inc. (San Diego, CA, USA) have entered into a partnership to expand the test menu on the Diazyme DZ-Lite c270 benchtop clinical chemistry analyzer, allowing it to run both special and routine chemistries.

In comparison to using time-consuming and labor-intensive immunoassay platforms, it is more economical to run tests on clinical chemistry analyzers. The DZ-Lite c270 is an advanced benchtop clinical chemistry analyzer with a menu of FDA-cleared, moderately complex, and innovative assays made for clinical laboratories of all sizes. The compact clinical chemistry analyzer supports 1, 2, 3, and 4-part reagent assays and has a throughput of up to 270 tests per hour. The analyzer can be used in all types of clinical laboratory settings such as reference laboratories, hospitals, and physician offices with clinical labs.

Related Links:
Carolina Liquid Chemistries, Corp. 
Diazyme Laboratories, Inc

New
Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
New
Urine Control
MassCheck Amino Acid Analysis Urine Controls
New
Celiac Disease Test
AESKULISA tTg-A New Generation

Print article

Channels

Molecular Diagnostics

view channel
Image: The test could be a game changer for people with some of the most aggressive forms of cancer (Photo courtesy of UNE)

Blood Test Could Help More Women Survive Aggressive Triple Negative Breast Cancer

Cancer research shows that over 90% of women diagnosed with breast cancer at its earliest stage survive for five years or more. However, this survival rate dramatically decreases to just 30% when the cancer... Read more

Pathology

view channel
Image: The Results Manager System (Photo courtesy of QuidelOrtho)

Informatics Solution Elevates Laboratory Efficiency and Patient Care

QuidelOrtho Corporation (San Diego, CA, USA) has introduced the QuidelOrtho Results Manager System, a cutting-edge informatics solution designed to meet the increasing demands of modern laboratories.... Read more
Sekisui Diagnostics UK Ltd.